Taking stock of the drug industry, from the lab to the medicine chest STAT+: U.S. appeals court panel decides AbbVie's 'patent thickets' for Humira don't thwart competition By Ed Silverman Aram Boghosian for STAT The court opinion shot down arguments by unions, insurers, and the city of Baltimore, which alleged that AbbVie “abused the patent system.” Read More STAT+: Medicare reverses course on plan to hide hospital safety data next year By Tara Bannow David Goldman/AP Medicare won’t stop publishing some hospital safety data next year after all. Regulators reversed course after backlash from patient safety groups. Read More STAT+: Alexis Borisy, biotech's 'man of many hats,' dons another By Allison DeAngelis Courtesy IDRx On Tuesday, Borisy launched a company called IDRx that plans to combine multiple drug compounds to create precise, durable cancer treatments. Read More Sponsor content by STAT Events STAT Event: Creating AI That Improves Health On August 3, hear how researchers aim to create a "data economy" to ensure that artificial intelligence lives up to its promise. Register now to join. Opinion: Paxlovid rebound happens, though why and to whom are still a mystery By Joan Bregstein Stephanie Nano/AP With more and more people taking the antiviral Paxlovid to treat early Covid-19, the number of rebound Covid cases will likely increase. Read More Tuesday, August 2, 2022 1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser
No comments